Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy

IJMS, Free Full-Text

Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma☆ - Annals of Oncology

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium - The Lancet Oncology

Increasing cure rates of solid tumors by immune checkpoint inhibitors, Experimental Hematology & Oncology

Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?

Neoadjuvant and adjuvant treatment received by patients with mucosal

Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy - Smithers - 2021 - ANZ Journal of Surgery - Wiley Online Library

The Miller Lab - Neoadjuvant Nivo/Rela for Resectable Melanoma

Schematic overview of the concept of adjuvant melanoma therapy and its